Condition: Advanced Triple-Negative Breast Cancer · Sponsor: BeBetter Med Inc
This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).
This description comes directly from the study's public registry record.
Kegang Jiang, Master · +86-18664786382 · kjiang@bebettermed.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06685796